VIMIAN logo

Vimian Group AB (publ)OM:VIMIAN Stock Report

Market Cap SEK 17.9b
Share Price
SEK 33.72
My Fair Value
AN
AnalystConsensusTarget
SEK 42
19.0% undervalued intrinsic discount
1Y-0.2%
7D-10.1%
Portfolio Value
​
View

Vimian Group AB (publ)

OM:VIMIAN Stock Report

Market Cap: SEK 17.9b

Vimian Group (VIMIAN) Stock Overview

Engages in the animal health business worldwide. More details

VIMIAN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance4/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 19.9% below our estimate of its fair value

Earnings are forecast to grow 44.61% per year

Earnings grew by 132.6% over the past year

Analysts in good agreement that stock price will rise by 23.5%

Risk Analysis

Significant insider selling over the past 3 months


VIMIAN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

VIMIAN logo
Vimian Group
AN
AnalystLowTarget
AnalystLowTarget
Consensus Narrative from 6 Analysts

Rising Interest Rates And Tariffs Will Weaken US MedTech Margins

Key Takeaways Reliance on acquisitions and exposure to rising rates and tariffs heighten operational risk and threaten predictable earnings and margin stability. Structural decline in key U.S. markets and digital disruption may erode market share, compress margins, and hinder long-term growth.
View narrative
SEK 37.32
FV
9.6% undervalued intrinsic discount
11.15%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
14 days ago author updated this narrative
VIMIAN logo
Vimian Group
AN
AnalystHighTarget
AnalystHighTarget
Consensus Narrative from 6 Analysts

Emerging Pet Trends And Digital Diagnostics Will Redefine Animal Healthcare

Key Takeaways MedTech and Specialty Pharma segments are poised for above-market organic growth and margin expansion through education, innovation, and accelerated product launches. Strategic acquisitions, rising global pet care demand, and digital healthcare investments bolster international diversification, margin gains, and long-term premium valuation potential.
View narrative
SEK 51.65
FV
34.7% undervalued intrinsic discount
12.55%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
17 days ago author updated this narrative
VIMIAN logo
Vimian Group
AN
AnalystConsensusTarget
AnalystConsensusTarget
Consensus Narrative from 6 Analysts

Digital Adoption And Niche Expansion Will Empower Veterinary Healthcare

Key Takeaways Sustained demand for advanced veterinary care and expansion in niche, high-margin segments position Vimian for recurring revenue and profit growth. Strategic acquisitions, digital adoption, and operational improvements support increased market share, new growth avenues, and recovery in underperforming areas.
View narrative
SEK 41.65
FV
19.0% undervalued intrinsic discount
9.82%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
about 3 hours ago author updated this narrative
View Stock Community

Vimian Group AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vimian Group
Historical stock prices
Current Share PriceSEK 33.72
52 Week HighSEK 47.30
52 Week LowSEK 31.45
Beta1.53
1 Month Change-15.70%
3 Month Change-13.45%
1 Year Change-0.24%
3 Year Change-18.90%
5 Year Changen/a
Change since IPO-58.32%

Recent News & Updates

Recent updates

If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity

Jun 17
If EPS Growth Is Important To You, Vimian Group (STO:VIMIAN) Presents An Opportunity

Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Jun 02
Estimating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely

May 15
Getting In Cheap On Vimian Group AB (publ) (STO:VIMIAN) Is Unlikely

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Mar 05
Is Vimian Group (STO:VIMIAN) A Risky Investment?

Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem

Feb 21
Vimian Group's (STO:VIMIAN) Earnings Are Weaker Than They Seem

A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)

Feb 14
A Look At The Fair Value Of Vimian Group AB (publ) (STO:VIMIAN)
author-image

iM3 Acquisition Will Expand Presence In Veterinary Dental Space

Expansion in Specialty Pharma and strategic focus on cash generation are expected to drive organic growth, enhancing revenue and margins.

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Dec 16
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Aug 31
Revenues Not Telling The Story For Vimian Group AB (publ) (STO:VIMIAN) After Shares Rise 27%

Is Vimian Group (STO:VIMIAN) A Risky Investment?

Aug 17
Is Vimian Group (STO:VIMIAN) A Risky Investment?

Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 18
Vimian Group (STO:VIMIAN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Apr 09
Vimian Group AB (publ) (STO:VIMIAN) Shares Could Be 40% Below Their Intrinsic Value Estimate

Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital

Feb 13
Vimian Group (STO:VIMIAN) Is Experiencing Growth In Returns On Capital

Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues

Jan 08
Little Excitement Around Vimian Group AB (publ)'s (STO:VIMIAN) Revenues

Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching

Dec 03
Why Vimian Group AB (publ) (STO:VIMIAN) Could Be Worth Watching

There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

Nov 01
There's Been No Shortage Of Growth Recently For Vimian Group's (STO:VIMIAN) Returns On Capital

Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price

Aug 27
Vimian Group AB (publ)'s (STO:VIMIAN) Intrinsic Value Is Potentially 92% Above Its Share Price

When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?

Jul 19
When Should You Buy Vimian Group AB (publ) (STO:VIMIAN)?

Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?

May 19
Are Investors Undervaluing Vimian Group AB (publ) (STO:VIMIAN) By 27%?

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Apr 04
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Jan 06
Calculating The Intrinsic Value Of Vimian Group AB (publ) (STO:VIMIAN)

Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Dec 09
Returns On Capital Are Showing Encouraging Signs At Vimian Group (STO:VIMIAN)

Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 38% Discount?

Aug 25
Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 38% Discount?

We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)

Jun 18
We Like These Underlying Return On Capital Trends At Vimian Group (STO:VIMIAN)

Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 34% Discount?

May 19
Is Vimian Group AB (publ) (STO:VIMIAN) Trading At A 34% Discount?

Shareholder Returns

VIMIANSE Medical EquipmentSE Market
7D-10.1%-1.1%-0.3%
1Y-0.2%-11.8%-2.9%

Return vs Industry: VIMIAN exceeded the Swedish Medical Equipment industry which returned -14.2% over the past year.

Return vs Market: VIMIAN exceeded the Swedish Market which returned -2.3% over the past year.

Price Volatility

Is VIMIAN's price volatile compared to industry and market?
VIMIAN volatility
VIMIAN Average Weekly Movement7.8%
Medical Equipment Industry Average Movement8.7%
Market Average Movement6.3%
10% most volatile stocks in SE Market13.5%
10% least volatile stocks in SE Market3.4%

Stable Share Price: VIMIAN has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: VIMIAN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20201,200Carl-Johan Boudrievimian.com

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the Indical Bioscience brand name.

Vimian Group AB (publ) Fundamentals Summary

How do Vimian Group's earnings and revenue compare to its market cap?
VIMIAN fundamental statistics
Market capSEK 17.94b
Earnings (TTM)SEK 254.85m
Revenue (TTM)SEK 4.52b
70.4x
P/E Ratio
4.0x
P/S Ratio

Is VIMIAN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIMIAN income statement (TTM)
Revenue€404.30m
Cost of Revenue€126.40m
Gross Profit€277.90m
Other Expenses€255.10m
Earnings€22.80m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Oct 22, 2025

Earnings per share (EPS)0.043
Gross Margin68.74%
Net Profit Margin5.64%
Debt/Equity Ratio40.1%

How did VIMIAN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/30 08:20
End of Day Share Price 2025/07/30 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vimian Group AB (publ) is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Hassan Al-WakeelBarclays
Blanka PorkolabBarclays